Almirall and simcere
WebSep 29, 2024 · Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group（2096.HK), an innovation and R&D … WebSep 29, 2024 · Almirall and Simcere enter licensing agreement for IL-2 mu-Fc SIM-0278 for autoimmune diseases Sep. 29, 2024 Almirall SA and Simcere Pharmaceutical …
Almirall and simcere
Did you know?
WebSep 29, 2024 · Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases. The Spanish ... WebSep 29, 2024 · Under the agreement, Almirall will be granted an exclusive right to develop and commercialise SIM0278 for all indications outside of the Greater China region (Mainland China, Hong Kong, Macau and Taiwan). Simcere will retain all rights to develop and commercialise SIM0278 within Greater China.
WebOct 12, 2024 · Simcere Pharmaceutical Group(2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall S.A. (BME: ALM), a global biopharmaceutical … WebSep 22, 2024 · Almirall and Ichnos Sciences signed an exclusive licence agreement for the IL-1RAP antagonist ALM27134 last December, granting Almirall global rights to develop and commercialise this monoclonal antibody for autoimmune diseases. Ichnos Sciences retained rights to antibodies targeting the IL-1RAP pathway for oncology indications.
WebSep 29, 2024 · Get 7 Days Free Sign In Sign In Topics WebSep 29, 2024 · NANJING, China, Sept. 28, 2024 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall …
WebOct 4, 2024 · Simcere Pharmaceutical Group has out-licensed its autoimmune drug candidate SIM-0278 for all indications to Almirall SA in a deal worth up to $507 million. Simcere granted exclusive global rights to the candidate to Almirall for development and commercialization excluding mainland China, Hong Kong, Macau, and Taiwan. In return, …
WebSep 29, 2024 · Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group（2096.HK), an innovation and R&D … mario murillo phone numberWebSep 29, 2024 · NANJING, China & BARCELONA, Spain-- (BUSINESS WIRE)-- Almirall S.A. (BME: ALM ), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group （2096.HK), an ... mario murillo wife roseWebNov 10, 2024 · In the third quarter, Almirall announced that it has entered into an exclusive licensing agreement with Simcere Pharmaceutical Group for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc ... mario murillo in california todayWebSep 29, 2024 · Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group （2096.HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune … mario muscarellaWebSimcere Pharmaceutical Group, an innovation and R&D-driven pharmaceutical company, and Almirall S.A, a global biopharmaceutical company focused on skin health; have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. mario musatWebSep 29, 2024 · NANJING, China, Sept. 28, 2024 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall … dana schwartz scottdale paWebSep 29, 2024 · Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases. mario murillo prophecies